Biotech

iCAD (NASDAQ:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2017. As quoted in the press release: “The fourth quarter was our strongest of the year from a revenue standpoint, as …

iCAD (NASDAQ:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2017.

As quoted in the press release:

“The fourth quarter was our strongest of the year from a revenue standpoint, as we closed out 2017 with particularly strong product revenue performance in our Artificial Intelligence detection software business,” said Ken Ferry, Chief Executive Officer of iCAD, Inc.  “The fourth quarter’s most significant catalyst was growing sales of PowerLook Tomo Detection software, the first Artificial Intelligence software product based on machine and deep learning that is commercially available for the detection of breast cancer on 3D mammograms.  We remain focused on maximizing the commercial potential for this key product, and customer feedback continues to be highly positive.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20633.28-62.89
TSXV769.97-13.72
DOW32899.37-98.60
S&P 5004123.34-23.53
NASD12144.66-173.03
ASX7205.60-159.10

COMMODITIES

Commodities
Gold1864.35-16.84
Silver22.04-0.24
Copper4.15-0.12
Palladium2044.41+17.41
Platinum939.50-17.50
Oil107.74-2.03
Heating Oil3.91-0.05
Natural Gas8.23+0.19

DOWNLOAD FREE REPORTS

×